目的 探討格列齊特緩釋片聯(lián)合利格列汀片治療2型糖尿病的臨床療效。方法 選取2015年6月-2017年4月天津醫(yī)科大學(xué)第二醫(yī)院內(nèi)分泌科收治的2型糖尿病患者120例為研究對(duì)象，根據(jù)隨機(jī)原則分成對(duì)照組和治療組，每組各60例。對(duì)照組口服利格列汀片，5 mg/次，1次/d。治療組在對(duì)照組基礎(chǔ)上口服格列齊特緩釋片，30 mg/次，1次/d。兩組患者均連續(xù)治療12周。觀察兩組的臨床療效，比較兩組的血糖水平、糖化血紅蛋白（HbA1c）、胰島素抵抗指數(shù)（HOMA-IR）和穩(wěn)態(tài)模型評(píng)估β細(xì)胞功能（HOMA-β）。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為83.33%、96.67%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組空腹血糖、餐后2 h血糖和HbA1c水平均顯著下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組空腹血糖和HbA1c水平明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組HOMA-IR顯著下降，HOMA-β顯著升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組HOMA-β明顯高于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 格列齊特緩釋片聯(lián)合利格列汀片治療2型糖尿病具有較好的臨床療效，可改善胰島素抵抗和胰島β細(xì)胞功能，安全性較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Gliclazide Modified Release Tablets combined with Linagliptin Tablets in treatment of type 2 diabetes mellitus. Methods Patients (120 cases) with type 2 diabetes mellitus in the Second Hospital of Tianjin Medical University from June 2015 to April 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were po administered with Linagliptin Tablets, 5 mg/time, once daily. Patients in the treatment group were po administered with Gliclazide Modified Release Tablets on the basis of the control group, 30 mg/time, once daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacies were evaluated, and blood glucose levels, HbA1c, HOMA-IR and HOMA-β in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 83.33% and 96.67%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of fasting blood glucose, postprandial 2 h blood glucose, and HbA1c in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the levels of fasting blood glucose and HbA1c in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the HOMA-IR in two groups was significantly decreased, but the HOMA-β in two groups was significantly increased, and the difference was statistically significant in the same group (P<0.05). And the HOMA-β in the treatment group was significantly higher than that in the control group, with significant difference between two groups (P<0.05). Conclusion Gliclazide Modified Release Tablets combined with Linagliptin Tablets has clinical curative effect in treatment of type 2 diabetes mellitus, can improve insulin resistance and beta cell function, with good safety, which has a certain clinical application value.